These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9260732)

  • 1. Phenytoin kinetics in Japanese adult epileptics: phenotype of phenytoin slow metabolizers.
    Watanabe M; Iwahashi K; Kugoh T; Suwaki H
    Clin Neuropharmacol; 1997 Aug; 20(4):346-51. PubMed ID: 9260732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients.
    Watanabe M; Iwahashi K; Kugoh T; Suwaki H
    Clin Neuropharmacol; 1998; 21(2):122-6. PubMed ID: 9579299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model.
    Odani A; Hashimoto Y; Takayanagi K; Otsuki Y; Koue T; Takano M; Yasuhara M; Hattori H; Furusho K; Inui K
    Biol Pharm Bull; 1996 Mar; 19(3):444-8. PubMed ID: 8924916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach.
    Yukawa E; Mamiya K
    J Clin Pharm Ther; 2006 Jun; 31(3):275-82. PubMed ID: 16789993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
    Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of Phenytoin Pharmacokinetic Parameters in Saudi Epileptic Patients.
    Alqahtani S; Alzaidi T; Alotaibi M; Alsultan A
    Pharmacology; 2019; 104(1-2):60-66. PubMed ID: 31067540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics.
    Mamiya K; Hadama A; Yukawa E; Ieiri I; Otsubo K; Ninomiya H; Tashiro N; Higuchi S
    Eur J Clin Pharmacol; 2000; 55(11-12):821-5. PubMed ID: 10805060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients.
    Deleu D; Aarons L; Ahmed IA
    Arch Med Res; 2005; 36(1):49-53. PubMed ID: 15777995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Hashimoto Y; Otsuki Y; Odani A; Takano M; Hattori H; Furusho K; Iui K
    Biol Pharm Bull; 1996 Aug; 19(8):1103-5. PubMed ID: 8874828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing the population pharmacokinetic parameters of phenytoin in adult epileptic patients in South Africa.
    Valodia P; Seymour MA; Miller R; McFadyen ML; Folb PI
    Ther Drug Monit; 1999 Feb; 21(1):57-62. PubMed ID: 10051055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age and phenytoin kinetics in adult epileptics.
    Bauer LA; Blouin RA
    Clin Pharmacol Ther; 1982 Mar; 31(3):301-4. PubMed ID: 7060313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of acute phase response on phenytoin metabolism in neurotrauma patients.
    McKindley DS; Boucher BA; Hess MM; Rodman JH; Feler C; Fabian TC
    J Clin Pharmacol; 1997 Feb; 37(2):129-39. PubMed ID: 9055139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
    Sachdeo RC; Sachdeo SK; Levy RH; Streeter AJ; Bishop FE; Kunze KL; Mather GG; Roskos LK; Shen DD; Thummel KE; Trager WF; Curtin CR; Doose DR; Gisclon LG; Bialer M
    Epilepsia; 2002 Jul; 43(7):691-6. PubMed ID: 12102670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy.
    Pattanaik S; Hota D; Prabhakar S; Kharbanda P; Pandhi P
    Phytother Res; 2006 Aug; 20(8):683-6. PubMed ID: 16767797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenytoin Michaelis-Menten pharmacokinetics in Saudi patients.
    el-Sayed YM; Islam SI
    Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):173-8. PubMed ID: 2714918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of bioavailability on the calculated Michaelis-Menten parameters of phenytoin in children.
    Koren G; Brand N; MacLeod SM
    Ther Drug Monit; 1984; 6(1):11-4. PubMed ID: 6710554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single oral loading dose of phenytoin: a pharmacokinetics study.
    Ratanakorn D; Kaojarern S; Phuapradit P; Mokkhavesa C
    J Neurol Sci; 1997 Mar; 147(1):89-92. PubMed ID: 9094065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticlopidine inhibits phenytoin clearance.
    Donahue S; Flockhart DA; Abernethy DR
    Clin Pharmacol Ther; 1999 Dec; 66(6):563-8. PubMed ID: 10613611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation.
    Ludden LK; Ludden TM; Collins JM; Pentikis HS; Strong JM
    J Pharmacol Exp Ther; 1997 Jul; 282(1):391-6. PubMed ID: 9223579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.